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Background: ADP-A2M10 speciﬁc peptide enhanced afﬁnity receptor (SPEAR) T-cells
are genetically engineered autologous T-cells that express a high-afﬁnity melanomaassociated antigen (MAGE)-A10-speciﬁc T-cell receptor (TCR) targeting MAGE-A10positive tumors in the context of human leukocyte antigen (HLA)-A*02. ADP-0022-004
is a phase 1, dose-escalation trial to evaluate the safety and anti-tumor activity of ADPA2M10 in three malignancies (https://clinicaltrials.gov: NCT02989064).
Methods: Eligible patients were HLA-A*02 positive with advanced head and neck
squamous cell carcinoma (HNSCC), melanoma, or urothelial carcinoma (UC) expressing
MAGE-A10. Patients underwent apheresis; T-cells were isolated, transduced with a
lentiviral vector containing the MAGE-A10 TCR, and expanded. Patients underwent
lymphodepletion with ﬂudarabine and cyclophosphamide prior to receiving ADPA2M10. ADP-A2M10 was administered in two dose groups receiving 0.1×10 9
and >1.2 to 6×109 transduced cells, respectively, and an expansion group receiving
1.2 to 15×109 transduced cells.
Results: Ten patients (eight male and two female) with HNSCC (four), melanoma (three),
and UC (three) were treated. Three patients were treated in each of the two dose groups,
and four patients were treated in the expansion group. The most frequently reported
adverse events grade ≥3 were leukopenia (10), lymphopenia (10), neutropenia (10),
anemia (nine), and thrombocytopenia (ﬁve). Two patients reported cytokine release
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syndrome (one each with grade 1 and grade 3), with resolution. Best response included
stable disease in four patients, progressive disease in ﬁve patients, and not evaluable in
one patient. ADP-A2M10 cells were detectable in peripheral blood from patients in each
dose group and the expansion group and in tumor tissues from patients in the higher dose
group and the expansion group. Peak persistence was greater in patients from the higher
dose group and the expansion group compared with the lower dose group.
Conclusions: ADP-A2M10 has shown an acceptable safety proﬁle with no evidence of
toxicity related to off-target binding or alloreactivity in these malignancies. Persistence of
ADP-A2M10 in the peripheral blood and trafﬁcking of ADP-A2M10 into the tumor was
demonstrated. Because MAGE-A10 expression frequently overlaps with MAGE-A4
expression in tumors and responses were observed in the MAGE-A4 trial
(NCT03132922), this clinical program closed, and trials with SPEAR T-cells targeting
the MAGE-A4 antigen are ongoing.
Keywords: HNSCC, melanoma, urothelial carcinoma, ADP-A2M10, MAGE-A10, adoptive cellular therapy, TCR

cell therapy must be antigen speciﬁc to the tumor and
demonstrate trafﬁcking to and inﬁltration throughout the tumor.
Cancer/testis antigens are an example of tumor-speciﬁc
antigens typically restricted to male germ cells in adults and
are overexpressed in several cancers. Targeting cancer/testis
antigens, including New York esophageal squamous cell
carcinoma antigen-1 and melanoma-associated antigen
(MAGE)-A4, has resulted in responses in patients with
advanced synovial sarcoma, melanoma, head and neck cancer,
non-small cell lung cancer, and esophagogastric cancer (11–15).
MAGE-A10 is a cancer/testis protein associated with many
cancers, including head and neck cancers, melanoma, and UC,
and is only expressed in normal tissue in immunologically
privileged sites such as testes and placenta (16–21). ADPA2M10 is an autologous speciﬁc peptide enhanced afﬁnity
receptor (SPEAR) T-cell product genetically engineered
through site-directed mutagenesis to express a TCR with
increased afﬁnity and speciﬁcity to a peptide (GLYDGMEHL)
derived from MAGE-A10 complexed with human leukocyte
antigen (HLA)-A*02:01 or A*02:06 (22). This SPEAR T-cell
product, ADP-A2M10, was engineered because MAGE-A10 is
expressed in many cancers and HLA-A*02:01 is expressed in
approximately 40% of people of European descent (23). This
phase 1 dose-escalation and expansion study (ADP-0022-004;
https://clinicaltrials.gov: NCT02989064) assessed the safety of
ADP-A2M10 for patients with advanced head and neck
squamous cell carcinoma (HNSCC), melanoma, or UC.

INTRODUCTION
Head and neck cancer, melanoma, and urothelial carcinoma (UC)
are associated with environmental carcinogens or pathogens (e.g.,
human papillomavirus, smoking, and sun exposure), have a high
non-synonymous mutational burden, and are responsive to
immunotherapeutic modalities (1). Although the overall tumor
mutational burden has been associated with improved efﬁcacy of
immunotherapy, it remains unclear how speciﬁc mutational
properties are associated with neoantigen presentation and
response to immunotherapy (2). In addition, although there are
effective treatments (including immunotherapy) for patients with
these diseases, there continues to be a signiﬁcant unmet medical
need in managing the emergence of therapy-resistant
advanced disease.
Adoptive cellular therapy is a cancer immunotherapy
approach that has been studied for the treatment of
hematologic and solid tumor malignancies. Primarily utilizing
tumor inﬁltrating lymphocytes, chimeric antigen receptor Tcells, or T-cell receptor (TCR) T-cells, responses have been
demonstrated with these adoptive cellular therapies in several
malignancies, paving the way for approval of several chimeric
antigen receptor T-cell therapies in hematologic malignancies
(3–7). Although tumor-inﬁltrating lymphocyte therapy has
shown activity in metastatic melanoma and cervical cancer
(8, 9), in order for engineered T-cell therapy to be successful in
the treatment of solid tumors [as has been demonstrated in
human papillomavirus-associated epithelial cancers (10)], the T-

MATERIALS AND METHODS
Abbreviations: ADP-A2M4, afamitresgene autoleucel; ADP-A2M10, ADPA2M10 SPEAR T-cells; AE, adverse event; CRS, cytokine release syndrome;
DLT, dose-limiting toxicity; HLA, human leukocyte antigen; HNSCC, head and
neck squamous cell carcinoma; IL, interleukin; MAGE, melanoma-associated
antigen; PD, progressive disease; PD-L1, programmed death ligand 1; RECIST,
Response Evaluation Criteria in Solid Tumors; SD, stable disease; SPEAR, speciﬁc
peptide enhanced afﬁnity receptor; TCR, T-cell receptor; UC,
urothelial carcinoma.
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Patient Eligibility and Trial Design
This multicenter, open-label, dose-escalation study included
patients between 18 and 75 years of age who were HLAA*02:01- and/or HLA-A*02:06-positive and h ad a
histologically conﬁrmed diagnosis of inoperable or metastatic
(advanced) HNSCC, melanoma, or UC (of the bladder, ureter,
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urethra, or renal pelvis) that expressed MAGE-A10
(Supplementary Methods). Patients received at least one prior
systemic therapy in the adjuvant or metastatic setting. For
patients with HNSCC, a platinum-containing chemotherapy
and/or immunotherapy was required for treatment in the
adjuvant or metastatic setting. For those with advanced
melanoma, a programmed death ligand 1 (PD-L1) inhibitor
and/or a cytotoxic T-lymphocyte-associated protein-4 inhibitor
were required and, in those with a BRAFv600 mutant melanoma,
a BRAF inhibitor or a combination of BRAF and MEK inhibitors
were required. Methods for HLA and MAGE-A10 testing are
described in the Supplementary Methods. Biopsies were given
both a MAGE-A10 P-score and H-score. The P-score was the
MAGE-A10 immunohistochemical positivity as determined by a
pathologist on the basis of both percentage of positive tumor cells
and intensity of expression. The H-score was derived from the
P-score by 1 × (% of 1+ cells) + 2 × (% of 2+ cells) + 3 × (% of 3+
cells). Patients had an Eastern Cooperative Oncology Group
Performance Status of 0–1; adequate renal, hepatic, and
hematological function; a left ventricular ejection fraction
of ≥50%; and measurable disease by Response Evaluation
Criteria in Solid Tumors (RECIST) v1.1 before
lymphodepletion (not required before leukapheresis) (24).
Eligible patients underwent leukapheresis for collection of
CD3+ T-cells to manufacture ADP-A2M10 (Supplementary
Methods and Figure 1). Patients were allowed treatment as
“bridging therapy” during the manufacturing of their ADPA2M10 cells and cytotoxic therapy, immunotherapy, and
targeted therapy were subsequently discontinued 3, 2, and 1
weeks, respectively, from lymphodepletion. Once the ADPA2M10 cells were available, eligibility criteria were
reconﬁrmed, and a baseline tumor assessment was obtained.
Patients then received lymphodepleting chemotherapy
consisting of cyclophosphamide 600 mg/m2 and ﬂudarabine 30
mg/m2 on days -7, -6, and -5. Given the importance of optimal
lymphodepletion for effective engraftment of the ADP-A2M10
product from prior trials (25), an additional day of ﬂudarabine
30 mg/m2 was incorporated on day -4 for group 3 and the

expansion group (Table 1). Patients received the ADP-A2M10
infusion on day 1, were hospitalized for a minimum of 3 days,
and were subsequently discharged at the investigator’s discretion.
As described in Table 1, ADP-A2M10 dose ranges were: group
1: 0.08 × 109 - 0.12 × 109 cells; group 2: 0.5 × 109 - 1.2 × 109 cells;
and group 3: >1.2 × 109 - 6.0 × 109 cells. Intervals of 21 days (dose
group 1) and 7 days (dose group 2 and dose group 3) between
dosing each patient were included to evaluate safety. No patients
were treated in dose group 2 because the group was removed from
the protocol based on the Safety Review Committee assessment of
safety data from patients in an identical dose group with the same
investigational agent in Study ADP-0022-003 (NCT02592577).
Therefore, ADP-A2M10 was escalated directly from group 1 to
group 3. Following the evaluation of safety for group 3, an
expansion group of up to 15 patients was dosed at 1.2 × 109 15 × 109 ADP-A2M10. The interventional phase lasted until
progressive disease (PD), after which patients were rolled over
into long-term follow-up for up to 15 years post-infusion or until
death or withdrawal.
Tumor biopsies were required at screening and optional at
baseline and after T-cell infusion. Screening biopsies were either
archival tumor samples or fresh samples required for eligibility.
Baseline biopsies were collected from 2 months to 1 week prior to
lymphodepletion, and post-infusion biopsies were collected from
week 3 to 12 after infusion.
The protocol and amendments were approved by the
institutional review board or ethics committee at each
participating site, and the trial was conducted in accordance
with the International Council for Harmonisation Good Clinical
Practice Guideline and the principles of the Declaration of
Helsinki. All patients provided written informed consent prior
to enrollment as per institutional guidelines. No patients or
members of the public were involved in the design of this
clinical trial.

Assessment of Toxicities and Responses
Safety and tolerability assessments were conducted at each study
visit as follows: baseline; day -7 to -3, 1–5, and 8; week 2, 3, 4, 5, 6,

FIGURE 1 | Study design. HLA, human leukocyte antigen; IHC, immunohistochemical; MAGE, melanoma-associated antigen; PD, progressive disease; SPEAR,
speciﬁc peptide enhanced afﬁnity receptor.

Frontiers in Oncology | www.frontiersin.org

3

March 2022 | Volume 12 | Article 818679

Hong et al.

ADP-A2M10: HNSCC, Melanoma, Urothelial Carcinoma

TABLE 1 | Dose groups – lymphodepletion and cell doses.
Dose group

Lymphodepletion regimen

Transduced cell dose
(range)

Dose group 1

Cyclophosphamide 600 mg/m2/day and ﬂudarabine 30 mg/m2/day on days -7, -6, and -5

Dose group 2a
Dose group 3

Cyclophosphamide 600 mg/m2/day and ﬂudarabine 30 mg/m2/day on days -7, -6, and -5
Cyclophosphamide 600 mg/m2/day on days -7, -6, and -5 and ﬂudarabine 30 mg/m2/day on days -7, -6,
-5, and -4
Cyclophosphamide 600 mg/m2/day on days -7, -6, and -5 and ﬂudarabine 30 mg/m2/day on days -7, -6,
-5, and -4

Expansion
group

Patient
ID

0.1×109 (0.08×109 to
0.12×109)
1×109 (0.5×109 to 1.2×109)
5×109 (>1.2×109 to 6×109)

–
4–6

5×109 (1.2×109 to 15×109)

7–10

1–3

a
No patients were treated in dose group 2 as this dose group was removed from the protocol based on the Safety Review Committee assessment of safety data from patients in an
identical dose group with the same investigational agent in Study ADP-0022-003 (NCT02592577).

8, 10, 12, 18, and 24; every 3 months until year 2; every 6 months
from year 2 to 5, or until disease progression; and throughout
long-term follow-up for up to 15 years. Adverse events (AEs) of
special interest were cytokine release syndrome (CRS), prolonged
cytopenia, neurotoxicity, and graft versus host disease. AEs were
graded in accordance with the National Cancer Institute
Common Terminology Criteria for Adverse Events v4.0, with
two exceptions. CRS was graded as described previously (26),
and prolonged cytopenias were graded as grade ≥3 neutropenia,
anemia, or thrombocytopenia in accordance with Common
Terminology Criteria for Adverse Events v5.0 and persisting
for ≥4 weeks from ADP-A2M10 treatment.
A dose-limiting toxicity (DLT) was deﬁned as a grade ≥3 AE
within the ﬁrst 30 days after administration of ADP-A2M10,
regardless of the investigator’s assessment of relationship to
ADP-A2M10. In evaluating potential DLTs, grade 3 or 4 CRS
resolving to grade ≤2 within 7 days and toxicities of any grade
considered attributable to the underlying malignancy,
lymphodepletion chemotherapy, or otherwise clearly unrelated
to the ADP-A2M10 were deemed not a DLT by the Safety
Review Committee.
Patients were followed for 15 years after treatment with
genetically modiﬁed T-cells in accordance with US Food and Drug
Administration and European Medicines Agency guidance (27–29)
to identify potential gene therapy-related delayed AEs, for molecular
replication competent lentivirus testing (quantitative PCR for the
vesicular stomatitis virus – G protein DNA sequence), and — if
necessary — for insertional oncogenesis (Supplementary Methods).
Efﬁcacy was evaluated using RECIST v1.1 at the following
study visits: baseline (within 7 days of lymphodepleting
chemotherapy); weeks 6, 12, 18, and 24, then every 3 months
until year 2; and every 6 months from year 2 to 5, or until disease
progression; and at completion. Although the evaluation of
response was done from the day of lymphodepletion, the
duration of response was assessed from day of ADP-A2M10
infusion (7 days after lymphodepletion).

in post-infusion tumor samples; and PD-L1 expression in preand post-infusion tumor samples.
Persistence of transduced ADP-A2M10 was assessed at
BioAgilytix (Boston, Massachusetts) by measuring the number
of copies of integrated lentiviral vectors (Psi element sequence)
per microgram of genomic DNA from peripheral blood, when
applicable, in bone marrow mononuclear cells by quantitative
PCR at the following time points: baseline; day 2, 4, and 8; week
2, 4, 6, 12, and 24; and every 3 months until year 2.
Levels of serum cytokines were collected at baseline; day 1–5,
and 8; week 2, 3, 4, 6, 12 and 24; and every 3 months and were
evaluated as previously described (25).
Transcriptomic analyses were performed at CellCarta
(Antwerp, Belgium) or the University of Texas MD Anderson
Cancer Center (Houston, Texas) as previously reported (25),
with modiﬁcations described in the Supplementary Methods.
The following gene signatures were used for analyses: antigen
processing machinery (30), CD3+ T-cells, CD8+ T-cells (31)
(NanoString Technologies, Seattle, Washington), and T-cell
exhaustion (32).
RNA in situ hybridization for ADP-A2M10 TCR was
performed on the Ventana Discovery Ultra automation
platform (Roche Diagnostics, Indianapolis, Indiana) using the
RNAscope 2.5 LS Red kit (Advanced Cell Diagnostics, Newark,
California) and RNAscope probes speciﬁc to ADP-A2M10 TCR
(Advanced Cell Diagnostics) according to the manufacturer’s
instructions. RNA in situ hybridization assay was followed by
CD3 chromogenic precipitate immunohistochemistry (anti-CD3
(2GV6), rabbit monoclonal primary antibody, Roche
Diagnostics, Indianapolis, Indiana) using the DISCOVERY
Teal horseradish peroxidase detection kit (Roche Diagnostics)
(Supplementary Methods).
PD-L1 expression was determined at a Clinical Laboratory
Improvement Amendments-certiﬁed and Belgian Accreditation
Organization and College of American Pathologists-accredited
laboratory (CellCarta, Antwerp, Belgium) or the University of
Texas MD Anderson Cancer Center (Houston, Texas) using PDL1 IHC 22C3 pharmDx (Agilent, Santa Clara, California). Tumor
Proportion Score and Combined Positive Score for PD-L1
expression were assessed as recommended by the manufacturer.

Translational Studies
Translational studies included the assessment of ADP-A2M10 Tcell persistence in peripheral blood and bone marrow, if
indicated; serum cytokine levels during CRS events;
transcriptomic analyses for antigen processing machinery,
CD3+ T-cells, and CD8+ T-cells; T-cell exhaustion evaluations
in pre-infusion tumor samples; presence of ADP-A2M10 T-cells
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Statistical Considerations
The primary objective was evaluation of the safety and tolerability
of ADP-A2M10. Secondary objectives were assessment of anti-
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as described. All 10 treated patients had at least one prior
systemic therapy (median: two; range: two to four). Nine
reported prior c he mo thera p y , n i n e r e p o rte d p ri o r
immunotherapy, two reported prior targeted therapy, and eight
reported prior radiotherapy.

tumor activity according to RECIST v1.1 and evaluation of
potential gene therapy-related delayed AEs. Exploratory
objectives were to assess the persistence of transduced ADPA2M10 in peripheral blood and their trafﬁcking into tumor
tissue, the production of cytokines during CRS events, and the
tumor and tumor microenvironment characteristics.
Progression-free survival, overall survival, and duration of
stable disease (SD) were summarized and graphically displayed
using the Kaplan-Meier method to estimate the 25th, 50th
(median), and 75th percentiles with corresponding 95% CIs.
The intent-to-treat population for analysis was deﬁned as all
eligible patients who were enrolled in the study. The modiﬁed
intent-to-treat population included all patients in the intent-totreat population who received at least one ADP-A2M10 infusion.
The modiﬁed intent-to-treat population was the primary
population for the safety and efﬁcacy analyses.

Treatment and AEs
Of the 10 treated patients, three in dose group 1, three in dose
group 3, and four in the expansion group were treated with ADPA2M10 within the dose range of 0.09 to 13.6×109 transduced
cells (Table 2). There were no DLTs during the dose-escalation
portion of the study and there were no apparent differences in
AE grades across the cell doses of ADP-A2M10 in the two dose
groups and the expansion group.
All 10 treated patients experienced at least one AE. AEs of
grade ≥3 occurring in ≥20% of patients are shown in Table 3.
The most common AEs reported were leukopenia/white blood
cells decreased, lymphopenia/lymphocyte count decreased, and
neutropenia/neutrophil count decreased, which occurred in all
10 patients. There were no grade 5 AEs.
Nine patients had AEs deﬁnitely, probably, or possibly related
to ADP-A2M10 therapy (Supplementary Table 2). The most
common related AEs were pyrexia, rash, and cytopenias. Two
patients (patients 9 and 10, expansion group) reported serious
AEs that were related to ADP-A2M10. Patient 9 developed grade
3 CRS, which resolved with treatment as described below. The
other (patient 10) developed several events, including grade 1
acute kidney injury and a grade 2 maculo-papular rash, which
both resolved, and pancytopenia, which was resolving at the time
of the patient’s death of PD as described below.
Of the 10 patients treated, two entered long-term follow-up;
however, they subsequently died due to PD. No AEs related to
gene-modiﬁed cell therapy were reported, all samples tested for
replication competent lentivirus were negative, and no patients
met the criteria for assessment of insertional oncogenesis.

RESULTS
Patient Characteristics
From September 2017 to September 2019, 10 patients underwent
lymphodepletion and were treated with ADP-A2M10
(Supplementary Results, Supplementary Table 1, and
Supplementary Figure 1). Of the 10 treated patients, patients
1–3, patients 4–6, and patients 7–10 were treated in dose group 1,
dose group 3, and the expansion group, respectively.
Demographic and baseline characteristics are detailed in
Table 2. The median age of the treated patients was 63 years
(range: 46–76 years), race included nine white and one other, and
ethnicity included nine non-Hispanic or Latino and only one
Hispanic or Latino. Four patients (patients 1, 2, 5, and 7) had
HNSCC, three patients (patients 3, 8, and 9) had cutaneous
melanoma, and three patients (patients 4, 6, and 10) had UC.
HLA and MAGE-A10 expression, and ADP-A2M10 cell dose are

TABLE 2 | HLA and MAGE-A10 expression, ADP-A2M10 dose, and response in individual patients (mITT) with various tumor types at screening.
Age
(years)
Sex

Tumor
Type

Prior
Therapya

HLA-A Allele
1/Allele 2

MAGE-A10 P-scoreb
(% <1+, 1+, 2+, 3+)

MAGE-A10
H-scorec

Actual ADP-A2M10
dose (cells ×109)

Response/(Max %Change
in SLD) DoSDd

1
2
3
4
5

66 M
61 M
47 M
58 M
46 F

HNSCC
HNSCC
Mel
UC
HNSCC

1, 2, 3, 4
1, 2, 4
1, 2, 4
1, 2, 4
1, 2, 4

0, 10, 30, 60
30, 20, 40, 10
0, 40, 30, 30
35, 40, 20, 5
5, 5, 70, 20

250
130
190
95
205

0.1
0.1
0.09
5.26
5.99

PD
NE
PD
SD (3.8%) 65 days
PD

6
7
8
9
10

66 M
76 M
47 F
65 M
68 M

UC
HNSCC
Mel
Mel
UC

1, 3
1, 2, 4
1, 2
2, 4
1, 2, 4

01:01 02.01
02:01 3:01
02:01 25:01
02:01 26:01
02:0
124:AUJRX
02:01 26:01
02:01 11:01
01:01 02:01
01:01 02:01
02:01 25:01

20, 30, 30, 20
0, 0, 20, 80
60, 5, 5, 30
10, 20, 50, 20
0, 5, 5, 90

150
280
105
180
285

5.51
3.97
4.87
6.53
13.63

SD (12.3%) 246 days
PD
PD
SD (1.1%) 122 days
SD (0%) 36 days

Patient
ID

a

1, Chemotherapy; 2, Immunotherapy; 3, Targeted therapy; 4, Radiotherapy.
P-score is immunohistochemical positivity determined by a pathologist based on both percentage of positive tumor cells and intensity of expression.
c
H-score is derived by 1 × (% of 1+ cells) + 2 × (% of 2+ cells) + 3 × (% of 3+ cells).
d
DoSD only analyzed in patients with SD.
DoSD, duration of stable disease; F, female; HLA, human leukocyte antigen; HNSCC, head and neck squamous cell carcinoma; M, male; MAGE, melanoma-associated antigen;
Mel, melanoma; mITT, modiﬁed intent-to-treat; NE, not evaluable; PD, progressive disease; SD, stable disease; SLD, sum of the longest diameters of the target lesions; UC, urothelial carcinoma.
b
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TABLE 3 | AEs in ≥20% of all patients of any grade and all patients of grade ≥3:
mITT population.
AEs by Preferred Term

Leukopenia/white blood cell count decreased
Lymphopenia/lymphocyte count decreased
Neutropenia/neutrophil count decreased
Anemia/red blood cell count decreased
Thrombocytopenia/platelet count decreased
Hyponatremia
Hypophosphatemia
Fatigue
Tumor pain
Rash
Pyrexia
Decreased appetite
Constipation
Hypotension
Hypocalcemia
Abdominal pain
Acute kidney injury
CRS
Dyspnea

enriched in bone marrow compared with peripheral blood
(Supplementary Figure 3).
Two patients (patients 9 and 8, expansion group) had
neurotoxicity, grade 1 intermittent somnolence, and grade 1
concentration impairment, respectively, possibly related to ADPA2M10. The patient with grade 1 intermittent somnolence had
this symptom associated with grade 3 CRS, which resolved in 1
day. Patient 8 with grade 1 concentration impairment was noted
to have this symptom beginning 6 days after ADP-A2M10 and
was ongoing at week 6 when the patient was noted to have PD.
There were no graft versus host disease events reported.

Number of patients (N = 10)
Any grade

Grade 3

Grade 4

10
10
10
9
6
6
4
7
3
5
6
5
4
4
3
2
2
2
2

0
0
0
9
1
5
1
2
2
0
1
1
1
1
1
1
1
1
1

10
10
10
0
4
0
1
0
0
1
0
0
0
0
0
0
0
0
0

Response Data
Nine of the 10 treated patients were evaluable for response by
RECIST v1.1 (Table 2). One patient (patient 2 with HNSCC)
progressed and died prior to evaluation. Four patients (patients
4, 6, and 10 with UC and patient 9 with melanoma) had SD and
ﬁve patients (three with HNSCC and two with melanoma) had
PD. Of the patients with SD, two patients were in dose group 3,
and two patients were in the expansion group.
The median progression-free survival for all patients was 46.5
days (range: 18–246 days), with median survival for dose group 3
at 65 days (range: 18–246 days) and for the expansion group at
46.5 days (range: 31–122 days). The median overall survival for
all patients was 171 days (range: 44–319 days), with median
survival for dose group 3 at 106 days (range: 59–250 days) and
for the expansion group at 236 days (range: 44–319 days). The
Kaplan-Meier estimate of median duration of SD was 122 days
(range: 36-246 days).
Of the 10 patients treated, one died prior to evaluation due to
PD while in the interventional phase. The remaining nine
patients were evaluable and ended the interventional phase due
to PD. Of these nine patients, three died due to PD prior to
entering long-term follow-up, three did not consent to long-term
follow-up, one withdrew consent prior to entering long-term
follow-up, and two entered long-term follow-up and
subsequently died due to PD.

AE, adverse event; CRS, cytokine release syndrome; mITT, modiﬁed intent-to-treat.

AEs of Special Interest
CRS was reported in two of the 10 treated patients (patients 7
and 9, expansion group) with severity of grade 1 and 3,
respectively, occurring on day 1 and 7, respectively, after ADPA2M10 infusion, and lasting only 1 day. Although patient 7 with
HNSCC received no treatment, patient 9 with melanoma and
grade 3 CRS received tocilizumab and methylprednisolone. A
transient increase in serum cytokines, including interferon g,
interleukin (IL)-6, IL-8, and IL-10, was observed after ADPA2M10 T-cell infusion in all patients. There was no marked
difference in serum cytokines (i.e., interferon g, IL-6, IL-8)
between those who had CRS and those who did not have CRS
(Supplementary Figure 2); however, the small sample limits the
conclusions that can be drawn.
Three patients experienced prolonged cytopenia. The ﬁrst
patient (patient 2, dose group 1) was noted to have pancytopenia
during week 2, which was treated with ﬁlgrastim and was
ongoing at the time of the patient’s death from PD during
week 7. The second patient (patient 4, dose group 3) had a
history of grade 2 anemia at baseline, which changed to grade 3
anemia following lymphodepletion and resolved to grade 2 on
week 4. However, from week 5 until week 11 of the interventional
phase, the patient had intermittent grade 3 anemia possibly
related to the patient’s prior lymphodepletion and subsequent
comorbidities. The third patient (patient 10, expansion group)
was noted to have pancytopenia on week 3, thought to be related
to lymphodepletion and ADP-A2M10. The patient underwent a
bone marrow biopsy, was found to have a hypocellular marrow
with panhypoplasia, and was treated with ﬁlgrastim/pegﬁlgrastim and eltrombopag. With cell counts demonstrating a
normal white blood cell and neutrophil count and grade 2
platelets and hemoglobin, the patient died of PD in week 6.
There was no evidence that ADP-A2M10 cells were
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Translational Studies
The persistence kinetics for ADP-A2M10-transduced cells varied
among patients. However, the presence of the transduced cells
was observed in all patients throughout the follow-up period and
up to 9 months post-infusion (Figure 2A). On average, peak
persistence was higher in patients from dose group 3 and
expansion group compared with patients from dose group 1
(Supplementary Table 3). Time to peak persistence was
comparable in patients across the groups (Supplementary
Table 3). Peak persistence trended higher in patients with SD;
however, the small sample limits the ability to draw
conclusions (Figure 2A).
ADP-A2M10 inﬁltration was examined in four biopsies
collected within 12 weeks after infusion. ADP-A2M10 was
observed in tumor samples of two SD patients treated in dose
group 3 and the expansion group: patient 6 with UC and patient
9 with melanoma (Figures 2B, C). T-cell inﬁltration was not
detected in the tumor tissue of two patients with PD: patient 3
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were core biopsies. Given the variation in size, these differences
in MAGE-A10 levels may be explained by inter- and intralesional tumor heterogeneity reported for UC and melanoma
(33, 34). Four and three post-infusion biopsies were available for
MAGE-A10 and PD-L1 expression evaluation, respectively.
There were no signiﬁcant effects of ADP-A2M10 cell infusion
on the expression of these proteins (Figures 3A, B). With limited
patient data, there was no evidence indicating that any of the
selected pre- and post-infusion tumor characteristics dictated the
response to the ADP-A2M10 therapy.

with melanoma from dose group 1 and patient 7 with HNSCC
from the expansion group (Figure 2C).
Among seven patients treated in both dose group 3 and the
expansion group, three patients with UC and one patient with
melanoma had SD, whereas two patients with HNSCC and one
patient with melanoma had PD. To investigate the lack of clinical
responses across indications, MAGE-A10 protein expression in
tumor cells pre- and post-infusion, PD-L1 protein expression in
tumor and stromal cells pre- and post-infusion, CD3+ T-cell,
CD8+ T-cell, T-cell exhaustion, and antigen processing
machinery gene expression pre-infusion were evaluated in
accordance with tumor sample availability. The characteristics
measured showed variability across patients and did not
signiﬁcantly differ between indications and response (Figure 3
and Supplementary Figure 4).
Interestingly, there were differences in MAGE-A10
expression in the screening biopsies of patients 6 (SD) and 8
(PD) collected 12 and 7 months before infusion, respectively, and
sequential baseline biopsies taken within 3 weeks before infusion.
Both baseline biopsies were negative for MAGE-A10 expression
based on the study cut-off (Figure 3A). The screening biopsies
were collected during resections whereas the baseline biopsies

DISCUSSION
ADP-0022-004 is a single-arm, open-label, phase 1, dose-escalation
study to assess ADP-A2M10 in advanced HNSCC, melanoma, and
UC. Ten patients were treated with lymphodepleting chemotherapy
followed by ADP-A2M10. Dose escalation, administering a target
of 5×109 ADP-A2M10, was safely completed, and the expansion
group commenced (up to 15 × 109 ADP-A2M10). There were no
DLTs in the dose-escalation phase. ADP-A2M10 with
lymphodepleting chemotherapy consisting of cyclophosphamide

A

B

C

FIGURE 2 | ADP-A2M10 were detected in peripheral blood and tumor tissue after infusion. (A) Persistence of ADP-A2M10 was measured by quantitative PCR of
the Psi element sequence in genomic DNA extracted from peripheral blood mononuclear cells. Data points are colored by response. (B) Representative ﬁelds for
detection of CD3+ and/or ADP-A2M10 TCR+ cells by CD3 immunohistochemical/RNA in situ hybridization assay in tumor tissue of patient 9 collected within 12
weeks after infusion. In the right image, CD3+ cells are shown in teal, ADP-A2M10 TCR+ cells are shown in purple, and nuclei are shown in light blue (hematoxylin
stain). (C) Result table for CD3 immunohistochemical/RNA in situ hybridization duplex assays reporting the detection of ADP-A2M10 in two of four post-infusion
tumor samples collected from the study patients. H&E, hematoxylin and eosin stain; HNSCC, head and neck squamous cell carcinoma; Mel, melanoma; NE, not
evaluable; PD, progressive disease; SD, stable disease; TCR, T-cell receptor; UC, urothelial carcinoma.
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A

B

FIGURE 3 | Variability of MAGE-A10 and PD-L1 expression in tumor tissue across the study patients. Pre-infusion (screening and baseline) and post-infusion
biopsies collected within 12 weeks after infusion were used for (A) MAGE-A10 expression and (B) PD-L1 expression evaluation. (A) MAGE-A10 expression was
assessed by MAGE-A10 immunohistochemical staining and plotted as percentage of tumor cells with 1+, 2+ and 3+ intensities. Horizontal lines designate the cut-off
of 10% of tumor with ≥1+ intensity of staining. (B) PD-L1 expression was assessed using PD-L1 IHC 22C3 pharmDx assay and plotted in terms of CPS. (A, B) Data
points are colored by response. Patient IDs are indicated by shape. CPS, Combined Positive Score; MAGE, melanoma-associated antigen; NE, not evaluable; PD,
progressive disease; PD-L1, programmed death ligand 1; Pre, pre-infusion; SD, stable disease.

600 mg/m2 for 3 days and ﬂudarabine 30 mg/m2 for 3 or 4 days was
associated with an acceptable safety proﬁle in this study. Cytopenias
were the most common AEs reported. Two patients had serious
AEs related to therapy (CRS in one patient; pancytopenia, maculopapular rash, and acute kidney injury in the other). Six patients
reported seven treatment-related AEs of special interest: prolonged
cytopenia (three events), CRS (two events, grades 1 and 3), and AEs
consistent with grade 1 neurotoxicity (two events).
Although there were four patients with SD, no objective
responses other than SD were reported. Factors that may
contribute to the efﬁcacy of autologous TCR-engineered T-cells
include antigen expression, T-cell dose, TCR expression levels,
tumor trafﬁcking and persistence in peripheral blood, and
immunosuppression (3, 4, 7). High expression of tumor-speciﬁc
antigens as designated by H-score has been associated with
responses in patients with synovial sarcoma (15, 25). Although
the MAGE-A10 H-score was ≥100 in most patients’ tumors, there
were no patients with partial response and no obvious differences
in MAGE-A10 expression in patients with SD or PD.
Furthermore, two patients had screening biopsies collected over
6 months before ADP-A2M10 infusions as well as baseline
biopsies taken within a 3-week period before ADP-A2M10
infusion. The screening biopsies were collected during resections
whereas the baseline biopsies were core biopsies. While both

Frontiers in Oncology | www.frontiersin.org

screening biopsies were positive for MAGE-A10, the baseline
biopsies were not. It is unclear whether these differences were
related to changes in expression levels with subsequent treatment
or variation in size of the biopsies. In addition, inter- and intralesional tumor heterogeneity has been reported for UC and
melanoma (33, 34). It is possible that this heterogeneity may
also contribute to the lack of response even in patients with a high
H-score. Nonetheless, larger tumor biopsies closer to the time of
treatment would be important in future studies.
While antigen expression may be required, it alone is not
sufﬁcient to result in a response without other contributing
factors such as cell dose and T-cell inﬁltration into the tumor
microenvironment. Anti-tumor responses have been more often
observed in those patients who received New York esophageal
squamous cell carcinoma antigen-1 transduced cell doses of
≥1×109 (11) and doses of ≥5×109 afamitresgene autoleucel
(ADP-A2M4) (15). Seven patients received a dose of ≥5×109
ADP-A2M10. Interestingly, SD was only demonstrated in those
patients. Additionally, four patients had post-treatment tumor
biopsies collected; and, importantly, ADP-A2M10 trafﬁcking
into the tumor was observed in two patients, both with SD and
with ADP-A2M10 cell doses >5×109. Moreover, peak persistence
trended higher in patients from dose group 3 and the expansion
group, and in those with SD. Although the limited number of
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patients with HNSCC, melanoma, and UC treated in this study
does not allow any ﬁrm conclusions to be drawn, there appears to
be a correlation toward a higher ADP-A2M10 cell dose of 5×109
and ADP-A2M10 trafﬁcking into the tumor, persistence, and SD.
Finally, the efﬁcacy of ADP-A2M10 therapy could be limited by
pre-existing and acquired intratumoral immunosuppression.
Novel combinations of SPEAR T-cell monotherapy with
approved drugs, such as checkpoint inhibitors, or development
of next−generation SPEAR T-cells co-expressing additional
immunoregulatory molecules, such as CD8a or IL-7/
chemokine (C-C motif) ligand 19, may increase anti-tumor
activity by overcoming immunosuppression and improving
clinical responses in patients with epithelial cancers (12, 35).
In this study, ADP-A2M10, an innovative autologous SPEAR
T-cell manufactured product, was successfully administered to
patients with several different solid tumor malignancies
expressing MAGE-A10. An acceptable safety proﬁle with no
evidence of toxicity related to off-target binding or alloreactivity
was demonstrated. Trafﬁcking of ADP-A2M10 cells in the blood
and to the tumor was conﬁrmed and peak persistence was greater
in patients from the higher dose groups compared with the lower
dose group. Four of the 11 patients had clinical beneﬁt with SD.
Nonetheless, among HLA-eligible patients with HNSCC,
melanoma, or UC, the frequency of positivity for the MAGEA10 antigen was lower than expected, making enrollment
challenging. While this trial was in progress, Study ADP-0044001 (NCT03132922) targeting the MAGE-A4 antigen with ADPA2M4 commenced and signiﬁcant responses were seen in
patients with non-small cell lung cancer, head and neck
cancer, and synovial sarcoma (13). Given data that MAGE
−A10 expression frequently overlaps with MAGE-A4
expression (Adaptimmune, data on ﬁle), this trial was closed
and several trials with adoptive cellular therapies targeting
MAGE-A4, including a registrational study in sarcoma, are
now ongoing (NCT03132922, NCT04044768, and
NCT04044859). Lastly, the ﬁndings from this study suggest
that targeting MAGE-A10 with this TCR could be further
optimized through improvements in T-cell manufacture,
enhancement of the phenotypic composition of the T-cell
product, or by targeting multiple antigens such as MAGE-A4
and A10 that are co-expressed in some tumors (as has been
recently explored in lymphoma (36)). Translational analyses,
including phenotyping of the patient’s manufactured product
and post-infusion T-cells for markers of immune activation and/
or exhaustion, may help the ﬁeld’s understanding of what may be
a desired phenotype for future T-cell products for mono- or
multi-antigen targeting T-cells. Furthermore, these analyses will
also contribute to understanding which patients may respond to
adoptive T-cell therapy with engineered afﬁnity-enhanced TCRs.
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Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, et al.
Tumor Immune Microenvironment Characterization in Clear Cell Renal Cell
Carcinoma Identiﬁes Prognostic and Immunotherapeutically Relevant Messenger
RNA Signatures. Genome Biol (2016) 17(1):231. doi: 10.1186/s13059-016-1092-z
Rhodes M, Danaher P, Dennis L, Mashadi-Hossein A, Irving L, Beechem J.
Using the PanCancer Immune Proﬁling Advanced Analysis Module (2019).
Available at: https://www.nanostring.com/wp-content/uploads/2020/12/WP_
MK1190_PanCancer_Immune_Proﬁling_Advanced_Analysis.pdf.
Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber
SH, et al. T-Cell Exhaustion Signatures Vary With Tumor Type and Are

March 2022 | Volume 12 | Article 818679

Hong et al.

33.

34.

35.

36.

ADP-A2M10: HNSCC, Melanoma, Urothelial Carcinoma

Immunomedics, Mereo BioPharma 5 Inc, NCI, PMV Pharma, Sanoﬁ, SeaGen,
TRACON Pharmaceuticals Inc., Triumvira, and Unum Therapeutics; advisory board
for BOLT Therapeutics. MB: grant/contract funding for investigator-initiated clinical
trials from Merck and Takara Bio; advisory boards for Adaptimmune, BMS, EMD
Serono, GlaxoSmithKline, Immunocore, Instil Bio, Iovance, Merck, Novartis, Pﬁzer,
and Sanoﬁ; has attended speaking engagements for BMS, Merck, Novartis, and
Pﬁzer; Safety Review Committees for Adaptimmune and GlaxoSmithKline.

Severe in Glioblastoma. Clin Cancer Res (2018) 24(17):4175–86. doi: 10.1158/
1078-0432.CCR-17-1846
Grzywa TM, Paskal W, Wlodarski PK. Intratumor and Intertumor
Heterogeneity in Melanoma. Transl Oncol (2017) 10(6):956–75.
doi: 10.1016/j.tranon.2017.09.007
Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor 3rd JA, Flaig TW, DeGraff DJ,
et al. Genomic Heterogeneity in Bladder Cancer: Challenges and Possible
Solutions to Improve Outcomes. Nat Rev Urol (2020) 17(5):259–70.
doi: 10.1038/s41585-020-0304-1
Cohen EE, Dunn L, Neupane P, Gibson M, Leidner R, Savvides P, et al.
SPEARHEAD-2 Trial Design: A Phase II Pilot Trial of ADP-A2M4 in
Combination With Pembrolizumab in Patients With Recurrent or
Metastatic Head and Neck Cancer. Ann Oncol (2020) 31(suppl_4):S685.
doi: 10.1016/j.annonc.2020.08.1091
Vasileiou S, Lulla PD, Tzannou I, Watanabe A, Kuvalekar M, Callejas WL,
et al. T-Cell Therapy for Lymphoma Using Nonengineered MultiantigenTargeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol
(2021) 39(13):1415–25. doi: 10.1200/JCO.20.02224

MF: consultant for Arcellx, BMS, Iovance, Kite, and Novartis. PF: employee of
Adaptimmune; holds stock in Adaptimmune and Bristol-Myers Squibb; has
received compensation for travel and congress meetings. RS: research support
from Amgen and Merck; has received fees as a consultant or SAB member from
Array Biopharma, Asana Biosciences, AstraZeneca, BMS, Eisai, Iovance, Merck,
Novartis, OncoSec, Pﬁzer, and Replimune. RP: grant funding from Janssen;
personal fees from AstraZeneca, Bayer, BMS, Dendreon, EMD, Genentech/
Roche, Genomic Health, Jounce Therapeutics, Merck, Sanoﬁ, and Serono/Pﬁzer;
nonﬁnancial support from BMS and Genentech/Roche.
The remaining authors declare that the research was conducted in the absence of
any commercial or ﬁnancial relationships that could be construed as a potential
conﬂict of interest.

Conﬂict of Interest: ABG: holds stock options in Adaptimmune. AS, DB, DM,
EN, FB, JB, J-MN, JS, RB, RW, SF, and ZW: employees of Adaptimmune. DH:
research/ grant funding from AbbVie, Adaptimmune, Aldi-Norte, Amgen,
AstraZeneca, Bayer, BMS, Daiichi-Sankyo, Deciphera, Eisai, Erasca, Fate
Therapeutics, Genentech, Genmab, Inﬁnity, Kite, Kyowa, Lilly, LOXO,
MedImmune, Merck, Mirati, Mologen, Navier, NCI-CTEP, Novartis, Numab,
Pﬁzer, Pyramid Bio, SeaGen, Takeda, Turning Point Therapeutics, Verastem, and
VM Oncology; compensation for travel, accommodations, and expenses from
AACR, ASCO, Bayer, Genmab, SITC, and Telperian; consulting, speaker, or
advisory roles for Acuta, Adaptimmune, Alkermes, Alpha Insights, Amgen,
Atheneum, AUM Biosciences, Axiom, Barclays, Baxter, Bayer, Boxer Capital,
BridgeBio, CDR-life AG, COG, COR2ed, Ecor1, Genentech, Gilead, GLG, Group
H, Guidepoint, HCW Precision, Immunogen, Inﬁnity, Janssen, Liberium,
Medscape, Numab, Oncologia Brasil, Pﬁzer, Pharma Intelligence, POET
Congress, Prime Oncology, Seattle Genetics, ST Cube, Takeda, Tavistock, Trieza
Therapeutics, Turning Point, WebMD, and Ziopharm; other ownership interests
in OncoResponse (Founder) and Telperian Inc (Advisor).

The authors declare that this study received funding from Adaptimmune Ltd. The
funder had the following involvement with the study: study design and analysis
and interpretation of the data.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their afﬁliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2022 Hong, Butler, Pachynski, Sullivan, Kebriaei, Boross-Harmer,
Ghobadi, Frigault, Dumbrava, Sauer, Brophy, Navenot, Fayngerts, Wolchinsky,
Broad, Batrakou, Wang, Solis, Duose, Sanderson, Gerry, Marks, Bai, Norry and
Fracasso. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) and the copyright owner(s) are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.

ED: grant/research support from Aileron Therapeutics, Amgen, Aprea Therapeutics,
Astex Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc., Bellicum
Pharmaceuticals, BOLT Therapeutics, Compugen Ltd, Immunocore LTD,

Frontiers in Oncology | www.frontiersin.org

11

March 2022 | Volume 12 | Article 818679

